---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-068297"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:32:28.092310+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics positive Phase 2b VOYAGE data: up to 75% NASH resolution with VK2809 vs 29% placebo (p=0.0001)

## Summary
- NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).
- Fibrosis improvement ≥1 stage with no NASH worsening: 44-57% for VK2809 vs 34% placebo (p<0.05 for 5 mg and 10 mg QOD, combined p=0.03).
- Combined endpoint (NASH resolution + fibrosis improvement) achieved by 40-50% vs 20% placebo (p<0.05 for 5 mg, 10 mg QOD, combined p=0.003).
- Liver fat reduction at 52 weeks: mean relative change -37% to -55%; ≥30% reduction in 64-88% of VK2809 patients (all p<0.0001 vs placebo).
- GI adverse events similar to placebo; discontinuation rates low; LDL-C reductions of 20-25% vs placebo (p<0.01).

## SEC filing metadata
- accession: 0000950170-24-068297
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024068297/0000950170-24-068297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024068297/vktx-20240604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-068297
- JSON: https://secwatch.observer/filing/0000950170-24-068297.json
- Plain text: https://secwatch.observer/filing/0000950170-24-068297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.